#Shionogi has reached a $2 billion agreement to buy Anglo-US biotech #IntraBio and its recently approved #Aqneursa therapy for two rare #geneticdisorders.
@pharmaphorum.bsky.social
@pharmaphorum.bsky.social#Shionogi has reached a $2 billion agreement to buy Anglo-US biotech #IntraBio and its recently approved #Aqneursa therapy for two rare #geneticdisorders.
@medchemexpress.bsky.social💊 #FDA Drug Approvals — September 2026
#Lirafugratinib, #Isembyld & #Zanvastro bring new approaches targeting FGFR, myostatin & RNA.
#Sevabertinib, #Camizestrant, #Imlunestrant, #Aqneursa & #Joenja expand therapeutic options across cancer, rare diseases & genetic disorders.
@medchemexpress.bsky.socialThe FDA has approved #Aqneursa (#levacetylleucine) oral suspension to treat ataxia in adults and pediatric patients with ataxia-telangiectasia (A-T) weighing ≥15 kg.
đź“ŠAqneursa improved neurological function as measured by the functional Scale for the Assessment and Rating of Ataxia (fSARA).
